The PharmaCompass Newsletter Sign Up, Stay Ahead Feedback, help us to improve
Research published in obesity medicine journals demonstrates that GLP-1 agonists like semaglutide increase thermogenesis, the process of heat production that consumes energy
Blood Sugar Drops and Cardiovascular Stability Non-diabetic users taking semaglutide rarely experience dangerous hypoglycemia because the drug's mechanism includes a glucose-dependent insulin responseinsulin release slows when glucose is already low
World Obesity Federation, World Obesity Atlas 2023 Unsurprisingly, weight loss medications have captured innovators attention as potential solutions, however, the obesity market has a history of many false dawns, as drugs in the past failed to deliver meaningful efficacy while some had serious safety issues, e.g., Fen-Phen, which was eventually withdrawn from the market due to cardiac risks 3